Hier finden Sie wissenschaftliche Publikationen aus den Fraunhofer-Instituten.

Safety and tolerability of indacaterol in asthma: A randomized, placebo-controlled 28-day study

: Chuchalin, A.G.; Tsoi, A.N.; Richter, K.; Krug, N.; Dahl, R.; Luursema, P.B.; Cameron, R.; Bao, W.; Higgins, M.; Woessner, R.; As, A. van


Respiratory Medicine 101 (2007), No.10, pp.2065-2075
ISSN: 0954-6111
Journal Article
Fraunhofer ITEM ()
long-acting Beta2-agonist; QAB149; Indacaterol; safety; tolerability; asthma

The safety and tolerability of indacaterol, a novel once-daily beta(2)-agonist bronchodilator with a fast onset of action, were assessed in 156 asthma patients in a multicentre, randomized, double-blind, placebo-controlled study. Patients received indacaterol 200, 400 or 600 mu g or placebo once daily for 28 days. Adverse events (AEs), laboratory assessments, vital signs, electrocardiograms, spirometry and physical examinations were monitored. Indacaterol pharmacokinetics were assessed. There was no evidence of dose-retated increases in AE incidence or clinically significant hypokalaemia or hyperglycaemia in indacaterol-treated patients. Mean pulse rate changes were minor in any group, with maximum 1-h post-dose changes from baseline of -3.7, -3.3 and -2.2bpm for indacaterol 200, 400 and 600 mu g, respectively, and -2.9bpm for placebo. Mean QTc interval was similar between groups; change from baseline >60 ms occurred in only two patients. Mean FEV1 increased after the first indacaterol dose; baseline-adjusted pre-dose (trough) values remained >= 166 mL higher than placebo at all subsequent visits, supporting a 24-h bronchodilator effect. Pre-dose (but not post-dose) serum indacaterol concentrations indicated a slight trend for accumulation. Once-daily indacaterol 200-600 mu g has a favourable therapeutic index. It is well tolerated, and is not associated with any adverse cardiac or metabolic effects, while providing effective 24-h bronchodilation.